NCT06778759

Brief Summary

In the present investigation the pain reduction effects of a physiotherapy technique combined with pharmaceutical ibuprofen arginine treatment will be compared to those produced by ibuprofen (only) treatment, in subjects who suffer the signs and symptoms of carpal tunnel syndrome.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
76

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Feb 2025

Shorter than P25 for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 12, 2025

Completed
4 days until next milestone

First Posted

Study publicly available on registry

January 16, 2025

Completed
1 month until next milestone

Study Start

First participant enrolled

February 19, 2025

Completed
21 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 12, 2025

Completed
7 days until next milestone

Study Completion

Last participant's last visit for all outcomes

March 19, 2025

Completed
Last Updated

December 11, 2025

Status Verified

December 1, 2025

Enrollment Period

21 days

First QC Date

January 12, 2025

Last Update Submit

December 3, 2025

Conditions

Keywords

Ibuprofen arginineMedian nerve neural mobilizationPain

Outcome Measures

Primary Outcomes (1)

  • Distal upper limb pain

    Assessed through the visual analog scale (VAS). The VAS is a psychometric response scale. It is a measurement instrument for subjective characteristics or attitudes that cannot be directly measured. The VAS is the most frequently used method to assess pain intensity. The scale will be displayed as a horizontal 10-cm line labelled at each end by descriptors such as 'no pain' (the minimum and best outcome possible) and 'worse pain ever' (maximum and worst outcome possible). The participant will mark the line to indicate pain severity and it is simply quantified by measuring the distance in centimeters from 0 (no pain) to the patient's marked rating.

    Through study completion, an average of 2 weeks. Changes from baseline (measured immediately before the application of the first treatment) and 40 minutes after the application of the last treatment

Secondary Outcomes (1)

  • Upper limb function

    Through study completion, an average of 2 weeks. Changes from baseline (measured immediately before the application of the first treatment) at 40 minutes after the application of the last treatment.

Other Outcomes (4)

  • Work Status at baseline

    Measured immediately before the application of the first treatment

  • Work Status post treatment

    Measured immediatly after the application of the last treatment.

  • Change in Work Task (Job Type)

    Measured immediatly after the application of the last treatment.

  • +1 more other outcomes

Study Arms (2)

Median nerve neural mobilization and oral ibuprofen arginine

EXPERIMENTAL

Median nerve neural mobilization, non pharmaceutical, non invasive, physiotherapy technique; which consists of a passive and repetitive upper limb movement that seeks to induce median nerve gliding and incursions against surrounding connective tissue. Subjects will be treated 5 days per week during a total time lapse of 2 weeks. This arm will also receive an oral ibuprofen arginine pharmaceutical treatment. Participants will be treated with a maximum of 1200 mg per day, subdivided in 3 intakes of 400 mg each 8 hours during a time lapse of 2 weeks

Combination Product: median nerve neural mobilization combined with oral ibuprofen arginine

Ibuprofen arginine

ACTIVE COMPARATOR

Participants will be treated with a maximum of 1200 mg of oral ibuprofen arginine tablets per day, subdivided in 3 intakes of 400 mg each 8 hours during a time lapse of 2 weeks

Drug: Ibuprofen Arginine

Interventions

Ibuprofen arginine oral tablets

Also known as: Spedifen
Ibuprofen arginine

Manual therapy maneuver performed in the upper limb combined with ibuprofen arginine oral tablets

Median nerve neural mobilization and oral ibuprofen arginine

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Participants must be medically diagnosed with unilateral carpal tunnel syndrome (with confirmative electrodiagnostic findings).
  • Full understanding of written and spoken Spanish (language).
  • Participants must freely consent to participate.
  • The presence of positive Phalen and Tinel signs.
  • The presence of carpal tunnel syndrome signs and symptoms

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ciudad Hospitalaria Enrique Tejera

Valencia, Carabobo, 02001, Venezuela

Location

MeSH Terms

Conditions

Carpal Tunnel SyndromePain

Interventions

ibuprofen arginine

Condition Hierarchy (Ancestors)

Median NeuropathyMononeuropathiesPeripheral Nervous System DiseasesNeuromuscular DiseasesNervous System DiseasesNerve Compression SyndromesCumulative Trauma DisordersSprains and StrainsWounds and InjuriesNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Francisco Unda, PhD

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Biomedicine Doctorate Program Investigator

Study Record Dates

First Submitted

January 12, 2025

First Posted

January 16, 2025

Study Start

February 19, 2025

Primary Completion

March 12, 2025

Study Completion

March 19, 2025

Last Updated

December 11, 2025

Record last verified: 2025-12

Data Sharing

IPD Sharing
Will not share

Locations